Published in Bioorg Med Chem Lett on September 22, 2011
The first example of the Fischer-Hepp type rearrangement in pyrimidines. Beilstein J Org Chem (2013) 0.78
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature (2008) 4.33
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell (2002) 2.54
Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr Biol (2006) 2.02
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res (2011) 1.79
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood (2005) 1.66
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol (2002) 1.64
The human Rad9/Rad1/Hus1 damage sensor clamp interacts with DNA polymerase beta and increases its DNA substrate utilisation efficiency: implications for DNA repair. Nucleic Acids Res (2004) 1.63
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol (2011) 1.53
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A (2004) 1.42
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol (2008) 1.41
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
The human Rothmund-Thomson syndrome gene product, RECQL4, localizes to distinct nuclear foci that coincide with proteins involved in the maintenance of genome stability. J Cell Sci (2005) 1.38
HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst (2012) 1.37
Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J Virol (2008) 1.35
Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One (2009) 1.35
Mechanisms of ATR-mediated checkpoint signalling. Front Biosci (Landmark Ed) (2010) 1.34
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem (2011) 1.26
Multifunctional role of Erk5 in multiple myeloma. Blood (2005) 1.22
TopBP1 and ATR colocalization at meiotic chromosomes: role of TopBP1/Cut5 in the meiotic recombination checkpoint. Mol Biol Cell (2004) 1.21
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Neuregulins and cancer. Clin Cancer Res (2008) 1.21
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood (2008) 1.17
HCLK2 is required for activity of the DNA damage response kinase ATR. J Biol Chem (2008) 1.17
Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem (2003) 1.16
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol (2007) 1.16
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica (2008) 1.13
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res (2005) 1.09
Mammalian BTBD12 (SLX4) protects against genomic instability during mammalian spermatogenesis. PLoS Genet (2011) 1.07
Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst (2010) 1.07
ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol (2006) 1.06
Bora and Aurora-A continue to activate Plk1 in mitosis. J Cell Sci (2013) 1.06
Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J (2002) 1.01
Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res (2010) 1.01
Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. Nucleic Acids Res (2013) 1.00
Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem (2006) 1.00
Opposing roles for 53BP1 during homologous recombination. Nucleic Acids Res (2013) 0.99
TopBP1 localises to centrosomes in mitosis and to chromosome cores in meiosis. Chromosoma (2004) 0.98
Telomere and telomerase modulation by the mammalian Rad9/Rad1/Hus1 DNA-damage-checkpoint complex. Curr Biol (2006) 0.97
Multisite phosphorylation of Erk5 in mitosis. J Cell Sci (2010) 0.95
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica (2008) 0.95
Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells (2013) 0.95
Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res (2008) 0.95
Deficient spindle assembly checkpoint in multiple myeloma. PLoS One (2011) 0.94
Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer (2005) 0.93
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol (2012) 0.93
Synthesis and antiproliferative activity of 2,4-disubstituted 6-aryl-7H-pyrrolo[3,2-d]pyrimidin-7-one 5-oxides. Bioorg Med Chem (2009) 0.92
A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. J Immunol Methods (2002) 0.92
Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther (2012) 0.92
Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem (2004) 0.91
Dot1-dependent histone H3K79 methylation promotes activation of the Mek1 meiotic checkpoint effector kinase by regulating the Hop1 adaptor. PLoS Genet (2013) 0.91
Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol (2006) 0.91
The Ddc2/ATRIP checkpoint protein monitors meiotic recombination intermediates. J Cell Sci (2011) 0.90
Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Res Treat (2010) 0.90
Synthesis and antiproliferative activity of (2R,3R)-disubstituted tetrahydropyrans. Bioorg Med Chem Lett (2006) 0.90
Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal (2006) 0.90
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One (2009) 0.89
Cell cycle-dependent processing of DNA lesions controls localization of Rad9 to sites of genotoxic stress. Cell Cycle (2009) 0.89
Erk5 is activated and acts as a survival factor in mitosis. Cell Signal (2007) 0.89
Do we have to change the way targeted drugs are developed? J Clin Oncol (2010) 0.88
The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev (2012) 0.88
Personalized therapies in the cancer "omics" era. Mol Cancer (2010) 0.88
Novel antiproliferative analogs of the Taq DNA polymerase inhibitor catalpol. Bioorg Med Chem Lett (2006) 0.88
Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal (2007) 0.88
A convenient synthesis of C-22 and C-25 stereoisomers of cephalostatin north 1 side chain from spirostan sapogenins. Org Lett (2002) 0.88
Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal (2013) 0.87
Conditional inactivation of the DNA damage response gene Hus1 in mouse testis reveals separable roles for components of the RAD9-RAD1-HUS1 complex in meiotic chromosome maintenance. PLoS Genet (2013) 0.86
Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res (2010) 0.86
Targeting HER receptors in cancer. Curr Pharm Des (2013) 0.85
The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant (2008) 0.85
Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1. Cell Div (2011) 0.85
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol (2008) 0.85
Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res (2013) 0.85
A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest (2004) 0.85
Anti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury model. PLoS One (2012) 0.83
Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol (2006) 0.83
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer (2014) 0.83
Abietane diterpenoids from Salvia pachyphylla and S. clevelandii with cytotoxic activity against human cancer cell lines. J Nat Prod (2006) 0.83
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia (2013) 0.82
Belizeanolide, a cytotoxic macrolide from the dinoflagellate Prorocentrum belizeanum. Angew Chem Int Ed Engl (2009) 0.82
Expression of DNA damage checkpoint protein Hus1 in epithelial ovarian tumors correlates with prognostic markers. Int J Gynecol Pathol (2008) 0.81
The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. Mol Biol Cell (2006) 0.81
Prins-type synthesis and SAR study of cytotoxic alkyl chloro dihydropyrans. ChemMedChem (2006) 0.81
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget (2015) 0.81